GullĂ , A
Hideshima, T
Bianchi, G
Fulciniti, M
Kemal Samur, M
Qi, J
Tai, Y-T
Harada, T
Morelli, E
Amodio, N
Carrasco, R
Tagliaferri, P
Munshi, N C
Tassone, P
Anderson, K C
Article History
Received: 9 August 2017
Revised: 4 October 2017
Accepted: 6 October 2017
First Online: 21 November 2017
Competing interests
: NCM serves on advisory boards to Millennium, Celgene and Novartis. KCA serves on advisory boards Celgene, Millennium and Gilead Sciences and is a Scientific founder of OncoPep and C4 Therapeutics. All other authors declare no competing financial interests.